Advances in Therapeutic Antibody Discovery and Development Targeting G Protein‐Coupled Receptors

G protein-coupled receptors (GPCRs) are integral to numerous biological processes and are associated with various diseases across all therapeutic areas. Consequently, GPCRs present substantial potential for antibody-based therapies. This review offers an overview of the therapeutic GPCR-antibody target landscape and examines the diversity within current therapeutic programs at different stages of the research and development pipeline. The progression of the GPCR-antibody pipeline demonstrates ongoing maturation, reflecting advancements that have addressed several longstanding technical challenges. Additionally, we discuss the rapid expansion of artificial intelligence and machine learning platforms designed to accelerate antibody discovery and clinical development, providing specific examples of their application to GPCRs.

Authors

Institutions

Publication Details

Journal
Pharmacology Research & Perspectives
Published
2026-01-20
DOI
https://doi.org/10.1002/prp2.70216
Primary Topic
Receptor Mechanisms and Signaling
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Advances in Therapeutic Antibody Discovery and Development Targeting G Protein‐Coupled Receptors

Serbülent Ünsal, Maria Waldhoer, Martin Culka, Catherine J. Hutchings et al.
Pharmacology Research & Perspectives
Receptor Mechanisms and Signaling
article

Advances in Therapeutic Antibody Discovery and Development Targeting G Protein‐Coupled Receptors

Serbülent Ünsal, Maria Waldhoer, Martin Culka, Catherine J. Hutchings, Mathieu Rappas, Ben Holland
article en

Abstract

G protein-coupled receptors (GPCRs) are integral to numerous biological processes and are associated with various diseases across all therapeutic areas. Consequently, GPCRs present substantial potential for antibody-based therapies. This review offers an overview of the therapeutic GPCR-antibody target landscape and examines the diversity within current therapeutic programs at different stages of the research and development pipeline. The progression of the GPCR-antibody pipeline demonstrates ongoing maturation, reflecting advancements that have addressed several longstanding technical challenges. Additionally, we discuss the rapid expansion of artificial intelligence and machine learning platforms designed to accelerate antibody discovery and clinical development, providing specific examples of their application to GPCRs.

Pharmacology Research & PerspectivesVol. 14(1)
University of Hertfordshire (GB), Hertfordshire County Council (GB), Redx Pharma (United Kingdom) (GB), Oldham Council (GB), Cardiff University (GB)
Openalex Percentile: Top 83%
Receptor Mechanisms and Signaling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Advances in Therapeutic Antibody Discovery and Development Targeting G Protein‐Coupled Receptors — Serbülent Ünsal, Maria Waldhoer, et al. · Pharmacology Research & Perspectives (2026) | TGRS Research Map | TGRS